Question 35

iPLEDGE program is for isotretinoin.

The iPLEDGE program is specifically designed to prevent fetal exposure to isotretinoin, a powerful medication used to treat severe acne. This program enforces strict guidelines for prescribing and dispensing isotretinoin to ensure the safety of pregnant women and unborn children.

A) isotretinoin

This option is correct because the iPLEDGE program was established to manage the risks associated with isotretinoin therapy, particularly the risk of teratogenicity. It requires patients to comply with specific requirements, including pregnancy testing and contraception use, to mitigate these risks.

B) warfarin

Warfarin is an anticoagulant medication used to prevent blood clots. While it does have risks associated with pregnancy, it is not managed under the iPLEDGE program. Therefore, this option is incorrect as it does not relate to the purpose of the iPLEDGE program.

C) digoxin

Digoxin is a medication used to treat various heart conditions and has no direct association with the iPLEDGE program. The iPLEDGE program focuses solely on isotretinoin, making this option incorrect.

D) finasteride

Finasteride is used to treat conditions like benign prostatic hyperplasia and male pattern baldness. Although it also has potential risks in pregnancy, it is not regulated by the iPLEDGE program, which is dedicated to isotretinoin. Thus, this option is incorrect.

Conclusion

The iPLEDGE program is uniquely focused on isotretinoin due to its significant risks during pregnancy, making it critical for patient safety. Options B, C, and D do not pertain to the iPLEDGE program, confirming that A is the only correct choice.